Rezpegaldesleukin for Eczema

(ZENITH AD-1 Trial)

This trial tests a new treatment called Rezpegaldesleukin for individuals with moderate to severe eczema (also known as atopic dermatitis). The goal is to evaluate the effectiveness and safety of this medicine compared to a placebo (a dummy treatment). Participants will receive either the new treatment or a placebo over several months, with administration every 2, 4, or 12 weeks. This trial may suit those who have had eczema for over a year and find that topical creams no longer work effectively. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to the potential availability of a new treatment.

The trial information does not specify if you need to stop taking your current medications. However, if you have used certain treatments like aldesleukin or systemic biologics before, you may not be eligible to participate.

Research has shown that Rezpegaldesleukin is generally safe for people. A review of several studies found the treatment well-tolerated, with no major safety concerns. Most side effects were mild to moderate, such as reactions at the injection site. Recent studies in atopic dermatitis, a skin condition, have not identified any new safety issues over longer periods. This suggests that Rezpegaldesleukin is safe for long-term use, making it a promising option for those with eczema.¹²³⁴⁵

Rezpegaldesleukin is unique because it targets interleukin-2 (IL-2) pathways, which is different from most current eczema treatments that primarily focus on suppressing the immune system or reducing inflammation. This novel approach could offer a more targeted treatment, potentially leading to fewer side effects. Additionally, its varied dosing schedules, from every two weeks to every twelve weeks, provide flexibility that might better suit individual patient needs and improve adherence. Researchers are excited because this could mean a more effective and convenient option for eczema patients, especially those who haven't responded well to existing therapies like topical steroids or calcineurin inhibitors.

Research has shown that Rezpegaldesleukin may help treat eczema. Studies found it significantly improved eczema severity scores, providing itch relief for many patients. Impressively, 71% to 83% of patients maintained significant improvement, known as EASI-75 responses, over time. The treatment also enhanced quality of life, with 72% of patients reporting major improvements in their daily lives. This trial will evaluate Rezpegaldesleukin's effectiveness for moderate to severe eczema, with participants receiving different dosing schedules or a placebo during the blinded induction and maintenance periods. These findings suggest Rezpegaldesleukin could be effective for moderate to severe eczema.²⁴⁶⁷⁸